Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines by Letra, L et al.
REVIEWARTICLE
Obesity as a risk factor for Alzheimer’s disease:
the role of adipocytokines
Liliana Letra & Isabel Santana & Raquel Seiça
Received: 21 July 2013 /Accepted: 3 February 2014 /Published online: 20 February 2014
# Springer Science+Business Media New York 2014
Abstract Alzheimer’s disease is the leading cause of demen-
tia and the most prevalent neurodegenerative disease. It is an
aging-related multi-factorial disorder and growing evidence
support the contribution of metabolic factors to what was
formerly thought to be a centrally mediated process. Obesity
has already been recognized as an important player in the
pathogenesis of this type of dementia, independently of insu-
lin resistance or other vascular risk factors. Although the exact
underlying mechanisms are still unknown, adipocyte dysfunc-
tion and concomitant alteration in adipocyte-derived protein
secretion seem to be involved, since these adipocytokines can
cross the blood–brain barrier and influence cognitive-related
structures. Very few studies have assessed the role of
adipocytokines dysfunction on cognitive impaired patients
and yielded contradictory results. Interestingly, extensive re-
search on the central effects of leptin in Alzheimer’s disease-
transgenic mice has demonstrated its capacity to enhance
synaptic plasticity and strength, as well as to prevent beta-
amyloid deposition and tau phosphorylation. In addition,
adiponectin, the most abundant adipocytokine whose levels
are inversely correlated to adiposity, has shown to be neuro-
protective to hippocampal cells. Many other adipose-derived
cytokines have mainly pro-inflammatory properties, being
able to trigger and/or enhance central inflammatory cascades
and also to influence the secretion of other adipocytokines
involved in cognition. This paper pretends to review the
existing evidence on the contribution of adipocytokines dys-
function to the increased risk of dementia associated with mid-
life obesity, unraveling its insulin-independent effects on
cognition.
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Introduction
The identification of modifiable risk factors is crucial for the
prevention of dementia, given the current limitations in its
treatment. While aging is still the most important risk factor
for late onset sporadic Alzheimer’s Disease (AD), several
studies have pointed high adiposity as an independent con-
tributor for the development of this type of dementia (Gorospe
and Dave 2007; Beydoun et al. 2008; Whitmer et al. 2008). In
fact, life-long relation between adiposity and cognition has
triggered some questions about the mechanisms by which
adipose tissue might influence cerebral structures related to
learning and memory, namely if its action is dependent on
insulin resistance state (Fig. 1).
It is well-known that midlife obesity is a major risk factor
for Type 2 Diabetes and these two disorders are frequently
associated. Thereby, for many years, the impact of adiposity
on AD incidence has been related to the effects of chronic
hyperinsulinemia on the blood–brain-barrier and insulin-
receptors activity that reduce insulin transport to the brain.
This so called “brain insulin resistance state” might in turn
increase Aβ toxicity, tau hyperphosphorylation, oxidative
stress and neuroinflammation, leading to neurodegeneration
(Son et al. 2011; Luchsinger et al. 2004). It seems though that
the influence of insulin metabolism on the clinical manifesta-
tion of AD is not constant over time. According to the
Rotterdam Study, levels of insulin and insulin resistance were
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associated with a higher risk of AD only within 3 years of
baseline (Schrijvers et al. 2010). Nevertheless, McNeilly et al.
(2012) showed that cognitive deficits observed in diet-
induced-obese animals were not prevented by insulin sensi-
tizers, while Leboucher et al. (2013) have shown that obesity
potentiate spatial learning deficits as well as hippocampal tau
pathology in τ-transgenic mice, independently of insulin re-
sistance state. Both of these studies have highlighted the
relevance of insulin-independent mechanisms in the increased
risk of dementia related to obesity. Adipose tissue is a highly
dynamic and metabolically active structure whose role has
been underestimated for several decades. It is the primary
storage site for excess energy, displaying characteristics of
an endocrine organ that secretes a number of adipocyte-
specific factors known as adipocytokines. These molecules
have metabolic, endocrine and inflammatory functions being
able to cross the blood–brain barrier and, therefore, carry out
its action on the brain (Kershaw and Flier 2004). In addition,
disturbance of the blood–brain barrier is common in dementia,
affecting central crossing of these adipose-derived compounds
(Gustafson 2006). Much of the research in this area has
focused leptin, the first adipocyte-derived signaling molecule
discovered, and more recently other adipocytokines, showing
evidence that these proteins might be actively implicated in
cognition. Therefore, we present a review of the existing data
on the contribution of obesity-related adipocytokine dysfunc-
tion to the increased risk of late onset AD.
Adiposity and adipocyte dysfunction
Adiposity has been traditionally defined as an increase in total
body mass, though visceral fat accumulation was found to
better correlate with a cluster of metabolic abnormalities
(Duvnjak and Duvnjak 2009). There are several adiposity
markers, but Body Mass Index (BMI) has been the most
widely used in clinical studies. Though BMI constitutes a
strong indicator of total body fat tissue, this correlation de-
creases with age (Luchsinger 2008) and does not provide
information on body composition neither distinguishes be-
tween visceral and subcutaneous fat (Cereda et al. 2007) while
fat is redistributed throughout life, especially during and after
middle age, from subcutaneous to intra-abdominal visceral
deposits (Raguso et al. 2006).
Other measures of adiposity are waist circumference and
waist-to-hip ratio, the first being more related to visceral fat
deposits and with stronger correlation with adverse metabolic
outcomes (Luchsinger 2008). Unfortunately, there are still no
standardized plasmatic biomarkers that could correlate more
directly with adipose tissue dysfunction.
In human obesity, adipose tissue alterations are far beyond
adipocyte hypertrophy or hyperplasia and its redistribution.
There are dynamic changes in its composition, mediated by
macrophages that are locally recruited and polarized toward
an inflammatory phenotype, associated with endothelial cell
activation and fibrosis. In fact, dysfunctional adipose tissue
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Fig. 1 Altered adipocytokine secretion in obesity and its pro-dementia
effects. Dysfunctional adipose tissue presents an overproduction of pro-
inflammatory adipocytokines (e.g. leptin, resistin) as well as reduced
secretion of anti-inflammatory and insulin-sensitizing compounds (e.g.
adiponectin). Despite peripheral hyperproduction of leptin in obese indi-
viduals, brain resistance develops. The same mechanism is proposed to
resistin, though laking more consistent data. Unlike the former cytokines,
adiponectin is inversely correlated to fat mass. Therefore its secretion
diminish when adipocytes become dysfunctional, compromising its neu-
roprotective effects. LTP long term potentiation, Aβ amyloid-beta,GSK-3b
glycogen synthase kinase beta, AMPK adenosine monophosphateactivated
protein kinase, S1p sphingosin-1-phosphate, NF-κB nuclear factor
kappa-light-chain-enhancer of activated B cells, IL interleukin, TNF-a tumor
necrosis factor alpha, MCP-1 monocyte chemoattractant protein-1, ROS
reactive oxygen species, RBP-4 retinol-binding-protein 4
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presents an overproduction of pro-inflammatory
adipocytokines (e.g. leptin) as well as a reduction of anti-
inflammatory and insulin-sensitizing compounds secretion
(e.g. adiponectin) (Maury and Brichard 2010). Since
adipokines are able to cross the blood–brain barrier, its
deregulated production may not only promote well-known
metabolic and cardiovascular detrimental outcomes, but also
be implicated in the obesity-dementia association. Misiak
et al. (2012) assumed that even subclinical inflammation of
adipose tissue could play a role in central inflammation,
triggering neurodegeneration cascades.
Adipocytokines implicated in cognition
Leptin
First described in 1994 (Zhang et al. 1994), leptin is the
primary adipose hormone that conveys a saciety signal to
the brain and its secretion is positively associated to the
amount of adipocytes. There is evidence that support that
leptin is not produced in the brain but actively transported
across the blood–brain barrier by a saturable system
(Kurrimbux et al. 2004; Banks et al. 1996). Its physiological
action in the hypothalamus results in decreased body weight
either by suppressing appetite and/or increasing energy ex-
penditure. Leptin also plays an important role in the regulation
of immune response, bone homeostasis, reproduction, and
mood and emotion (Morris and Rui 2009). Besides this pleio-
tropic role, leptin has shown to promote beneficial effects on
memory, including enhancement of long-term potentiation
with consequent cognitive improvement when directly admin-
istered on dentate gyrus or CA1 hippocampal region (Shanley
et al. 2001; Wayner et al. 2004) and also to influence hippo-
campal synaptic plasticity by enhancing N-methyl-D-aspar-
tate (NMDA) receptors (Durakoglugil et al. 2005). Data from
cell cultures and AD animal models show evidence of the role
of this adipocytokine in amyloid precursor protein (APP)
metabolism, namely a reduction of amyloid-beta (Aβ) peptide
production by blocking β-secretase activity and increasing
Apolipoprotein E (ApoE) dependent Aβ uptake (Fewlass
et al. 2004). Moreover, leptin seems to promote phosphoryla-
tion (and deactivation) of glycogen synthase kinase beta
(GSK-3β), the main responsible for abnormal tau phosphor-
ylation (Greco et al. 2009). Additionally, Li et al. (2012)
demonstrated that obese leptin-resistant-mice (db/db) had
multiple AD-like brain changes including increased
phospho-tau and Aβ as well as decreased synaptic proteins,
with consequent impairment of their performance in cognitive
tasks. They also reported that metformin, a well-known anti-
diabetic agent, attenuates AD brain-like biochemical changes
but not memory and spacial learning deficits. This suggests
that other mechanisms, rather than insulin resistance sole,
contribute to cognitive impairment in these obese mice.
Despite extensive animal research on leptin, there are limited
studies in human populations. A subgroup of the Framingham
cohort and the Health ABC Study have demonstrated that
higher leptin levels were associated with lower dementia risk
and higher brain volume 7,7 or 4 years after leptin was
assayed, respectively (Lieb et al. 2009; Holden et al. 2009).
On the other hand, Rajagopalan et al. (2013) reported that
elderly with higher leptin levels (obese) showed concomitant
greater global brain atrophy, highlighting the deleterious effect
of central leptin insufficiency associated with obesity. In fact,
despite peripheral hyperproduction of leptin in obese individ-
uals, brain resistance to its action will also develop. Bonda
et al. (2014) demonstrated recently that besides up-regulation
of leptin in AD patients’ CSF and hippocampus, leptin recep-
tor mRNA was decreased in the brain tissue and its protein
was localized to neurofibrillary tangles. Interestingly, leptin
CSF levels showed a positive relation with the Braak staging
(plaque and tangle distribution at different stages of
Alzheimer’s disease progression) and were independent of
age and BMI. It would be helpful to correlate these findings
with adiponectin levels (in plasma and CSF) once the equation
leptin/adiponectin is a more reliable marker of adipose tissue
dysfunction and consequently of its metabolic effects (Satoh
et al. 2004).
Adiponectin
Adiponectin (ACRP30) is the most abundant adipocytokine,
presenting in plasma in globular, trimer, hexamer and high–
molecular weight (HMW) isoforms (Fruebis et al. 2001;
Takemura et al. 2007). Unlike leptin, adiponectin secretion
is inversely correlated with fat mass and promotes anti-
inflammatory, antiangiogenic, antiatherogenic and
vasodilatory action, exerting also beneficial effects on lipid
and glucose profiles (Gustafson 2010). It is a peptide mainly
produced by adipose tissue, without solid evidence of intra-
cerebral production, and is able to act as a central regulator of
energy homeostasis. The expression of two key receptors of
adiponectin, AdipoR1 and AdipoR2, was observed in hippo-
campal neurons, and the neuroprotective role of adiponectin
was proven, particularly in excitotoxic conditions (Jeon et al.
2009; Qiu et al. 2011). Neuroprotection is then mediated by
adenosine monophosphate-activated protein kinase (AMPK)
activation, which seems to minimize neural insult acting as a
regulatory factor between neuronal growth and death in re-
sponse to stress (Erol 2008), though recent data have
highlighted the role of sphingolipid metabolism in the pleio-
tropic effects of adiponectin. In fact, activation of its receptors
stimulates intracellular catabolism of ceramide, increasing the
levels of its anti-apoptotic metabolite sphingosin-1-phosphate
(S1p) (Holland et al. 2011; Turer and Scherer 2012).
Additionally, Chan et al. (2012) raised the possibility that
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NF-κB (nuclear factor kappa-light-chain-enhancer of activat-
ed B cells) suppression represents another mechanism under-
lying the effect of adiponectin against Aβ-induced neuronal
cytotoxicity. A third receptor recently described, T-cadherin,
remains with unclear brain expression and pathophysiologic
significance, despite recognized importance in adiponectin-
mediated cardioprotection.
Involvement of adiponectin in AD or its prodromal stage
(Mild Cognitive Impairment – MCI) has also been investigat-
ed in clinical studies, although in a limited number and with
contradictory results. J-SHIPP Study (Shimanami Health
Promoting Program - Kamogawa 2010) was the first cross-
sectional study to investigate abdominal fat distribution in
individuals with MCI and was able to demonstrate the asso-
ciation between this prodromal stage and lower levels of
plasma adiponectin (only in men), while Une et al. (2011)
showed higher concentrations of plasma and cerebrospinal
fluid (CSF) adiponectin in MCI compared with normal con-
trols. According to the authors, this could play a role in the
weight loss observed in the early stages of dementia. In our
point of view, it could also translate a protective effort against
a neurotoxic insult. More recently, Teixeira et al. (2013)
demonstrated that circulating adiponectin levels were reduced
in MCI and AD patients but did not predict progression to
dementia. On other hand, Bigalke et al. (2011) and Warren
et al. (2012) failed to demonstrate a correlation between
plasmatic levels of this adipocytokine and AD. Nonetheless,
correlation of these data with CSF adiponectin levels and
dementia biomarkers, such asβ-amyloid, tau and phosphotau,
is still lacking and conflicting results from these few studies
have not yet been elucidated. Future experiments should focus
on the dynamics of adiponectin and its receptors on brain
tissue, namely on hippocampus, once alterations in its struc-
ture and function are hallmarks of AD.
Interestingly, Pákáski et al. (2014) recently demonstrated
that donepezil, an acetylcholinesterase inhibitor currently used
in AD therapy, is able to regulate serum adipokines by reduc-
ing leptin and enhancing adiponectin. These findings are
consistent to what was previously exposed, reinforcing the
role of adipokines in the pathomechanism of AD.
Visfatin and RBP-4
Visfatin or Nicotinamide phosphoribosyltransferase
(NAMPT) is a key enzyme in the synthesis of nicotinamide
adenine dinucleotide (NAD), ubiquitously expressed and
widely distributed in visceral adipose tissue and brain, includ-
ing hippocampus and cerebral cortex. Its biological role is not
entirely understood mas it seems to be insulin-sensitizer and a
pro-inflammatory citokine (Al-Suhaimi and Shehzad 2013).
Elevated serum levels of this protein have been associated
with obesity and normal aging though brain levels are re-
duced, compromising NAD biosynthesis and promoting
neurodegeneration (Adams 2008; Liu et al. 2012). A direct
effect of this protein on the pathophysiology of AD remains
unclear.
Retinol-binding-protein-4 (RBP-4), whose main function
is to deliver vitamin A to tissues, was described by Yang and
colleagues (2005) as an adipocytokine, though mainly secret-
ed by hepatocytes. It seems to have a direct relation to BMI
and a still controversial relation with insulin resistance (Rocha
et al. 2013). Natural ageing is associated with a reduction in
the retinoid levels in the central nervous system, which are
dependent on the diet supply, transportation to the brain and
the production/removal of end products (Goodman 2006).
Retinoid receptors are preferentially located in structures in-
volved in cognition (cerebral cortex, amygdala, hypothala-
mus, hippocampus and striatum), and there is evidence that
they participate in synaptic plasticity as well as in learning and
memory processing (Lane and Bailey 2005). Accordingly,
several studies have already demonstrated that disruption of
retinoid signaling pathways is directly implicated in the path-
ophysiology of Alzheimer’s disease, namely in the
amyloidogenic pathway (Misner et al. 2001; Husson et al.
2006; Corcoran et al. 2004). Whether obesity-related adipo-
cyte dysfunction contributes to this central retinoid disruption
remains unclear.
Resistin Resistin is an adipose tissue-specific hormone that
antagonizes insulin action. Circulating resistin levels are de-
creased by anti-diabetic drugs such as rosiglitazone, and in-
creased in diet-induced and genetic forms of obesity (Steppan
et al. 2001). Recently, Lu et al. (2013) and Liu et al. (2013)
demonstrated that this adipokine has neuroprotective effects.
The first showed that resistin reduces 6-OHDA-induced apo-
ptotic cell death in dopaminergic-like cells, which is accom-
plished by inhibiting oxidative stress and apoptosis. On the
other hand, Liu et al. (2013) were the first to describe the
protective effects of resistin against Aβ-induced neurotoxicity
in AD. The mechanisms proposed include decrease levels of
reactive oxygen species, improvement of mitochondrial func-
tion and prevention of apoptosis, though no changes were
observed in the production of Aβ. However, the exact recep-
tors that mediate these actions and whether there is a brain
resistin-resistance state or more significant pro-inflammatory
adverse effects in obese require further investigation.
Other pro-inflammatory cytokines
As previously discussed, there is a clear association between
dysfunctional adipose tissue and low-grade inflammation due
to increased secretion of numerous pro-inflammatory cyto-
kines from hypertrophic adipocytes and recruited macro-
phages. Many of these cytokines are increased in obesity
and may play an important role in several pathologies, includ-
ing dementia, by promoting angiogenesis, inflammation, cell
proliferation, and insulin resistance (Kim et al. 2011).
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Interleukin-6 (IL-6) is a protein that exerts an inhibitory
action on adiponectin secretion (Kamogawa et al. 2010) and
has peripheral and central adverse effects, being the hippocam-
pus particularly vulnerable to its pro-inflammatory action.
Tumor necrosis factor-alpha (TNF-α) levels strongly correlate
with BMI (Takemura et al. 2007) and have been implicated in
the demential process, though inconsistently (Une et al. 2011).
Guerreiro et al. (2007) showed that in MCI and AD patients
there was a significant raise in the percentage of monocytes
producing pro-inflammatory interleukins (IL-1β, IL-6, IL-12)
and TNF-α when compared with healthy controls. MCP-1
(monocyte chemoattractant protein-1, or CCL-2) has a key role
in the recruitment of monocytes/macrophages into adipose
tissue being also produced by neurons and glial cells, activating
its receptor (CCR2) and contributing to pathological
microgliosis and exacerbation of Aβ pathology in animal
models of AD. In humans with dementia, MCP-1 levels are
increased in CSF and in the brain tissue (MCP-1 co-localizes
with senile plaques); however, only MCP-1 levels in the CSF,
and not in plasma, were associated with faster cognitive decline
in patients withMCI. This indicates that MCP-1-related inflam-
matory processes that are relevant for the disease progression
are primarily localized in the brain, and probably not directly
associated with peripheral tissue disorders (Westin et al. 2012).
The relation between cognitive impairment and these inflam-
matory markers, which are not adipocyte-specific but are, in-
stead, diffusely produced, is beyond the scope of this review.
Conclusion
In the past few years it has became increasingly clear that
adipocyte dysfunction influences the risk and/or the rate of
cognitive decline. Beyond its peripheral metabolic effects,
several adipocytokines have been consistently implicated in
this process, exerting differential protective or deleterious
effects on cognitive-related structures. In our opinion, some
of the conflicting results published to date may be explained,
at least in part, by an “obesity paradox” in the assessment of
the risk of dementia and its correlation to adiposity in different
stages of life. Additionally, more accurate and standardized
measures of adiposity are lacking.
Considering cognitive epidemiology, it seems reasonable
to admit that Alzheimer Disease is a metabolic disorder, which
incidence could be reduced with prevention policies.
Therefore, efforts to understand metabolic signaling pathways
associated with AD, namely those involved in adipocyte-brain
axis, should continue, while facing discouraging results in the
search for specific treatment options.
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